Значення супресії функції яєчників у лікуванні хворих на рак молочної залози у пременопаузі

І. Б. Щепотін; О. С. Зотов; Р. В. Любота; І. І. Любота

doi:10.24026/1818-1384.1(42).2013.77415

Автор(и)

І. Б. Щепотін Національний інститут раку, Київ, Україна
О. С. Зотов Національний медичний університет імені О.О. Богомольця, Київ, Україна
Р. В. Любота Національний медичний університет імені О.О. Богомольця, Київ, Україна
І. І. Любота Київський міський клінічний онкологічний центр, Київ, Україна

DOI:

https://doi.org/10.24026/1818-1384.1(42).2013.77415

Ключові слова:

breast cancer, adjuvant hormonal therapy, ovarian ablation, premenopausal

Анотація

Hormone therapy is the oldest method of systemic treatment of patients with breast cancer. There are several methods of ovarian ablation: surgery, medication or radiation castration. Currently, there are no clinical studies that aim to compare the effectiveness of different methods of ovarian ablation, so considered that different methods of ovarian ablation are equally effective. In this review included 10 randomized trials involving 11135 patients, which examined the effectiveness of the ovarian ablation in premenopausal women with breast cancer. The results of these studies allow to optimized the use of ovarian ablation in patients with breast cancer.

Біографії авторів

І. Б. Щепотін, Національний інститут раку, Київ

I. Schepotin

О. С. Зотов, Національний медичний університет імені О.О. Богомольця, Київ

A. Zotov

Р. В. Любота, Національний медичний університет імені О.О. Богомольця, Київ

R. Lubota

І. І. Любота, Київський міський клінічний онкологічний центр, Київ

I. Lubota

Посилання

Моисеенко В. М., Семиглазов В. В., Тюляндин С. А. Современное лекарственное лечение местно-распространенного и метастатического рака молочной железы. С.-Пб.: Грифон, 1997. - 254 с.

Baum M., Hackshaw A., Houghton J., et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study // European Journal of Cancer. – 2006. – Vol. 42, No7. – P.895-904. https://doi.org/10.1016/j.ejca.2005.12.013

Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases // Lancet. – 1896. – Vol. 148, No3802. – P. 104-107. https://doi.org/10.1016/s0140-6736(01)72307-0

Berry D.A., Cirrincione C., Henderson I.C. et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer // JAMA. – 2006. – Vol. 295, No 14 – P. 1658-1667. https://doi.org/10.1001/jama.295.14.1658

Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer // Journal of Clinical Oncology. – 1998. – Vol. 19, N 14. – P. 1718-1729.

Cuzick J., Ambroisine L., Davidson N. et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials // Lancet. – 2007. – Vol. 369, N 9574. – P. 1711-1723. https://doi.org/10.1016/s0140-6736(07)60778-8

Davidson N.E., O'Neill A.M., Vukov A.M. et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188) // Journal of Clinical Oncology. – 2005. – Vol. 23, N 25. – P. 5973-5982. https://doi.org/10.1200/jco.2005.05.551

Fisher B., Anderson S., Tan-Chiu E. et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23 // Journal of Clinical Oncology. – 2001. – Vol.19, N 14. – P. 931-942.

Forward D.P., Cheung K.L., Jackson L., Robertson J.F. Clinical and endocrine data for goserelin plus anastrozole as secondline endocrine therapy for premenopausal advanced breastcancer // British Journal of Cancer. – 2004. – Vol. 90, N 3. – P. 590-594. https://doi.org/10.1038/sj.bjc.6601557

Gnant M., Mlineritsch B., Schippinger W. et al. Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer // New England Journal of Medicine. – 2009. – Vol. 360, N 7. – P. 679-691. https://doi.org/10.1056/nejmoa0806285

Jakesz R., Hausmaninger H., Kubista E. et al. Randomised adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in pre-menopausal patients with hormone responsive breast cancer – Austrian Breast and Colorectal Cancer Study Group trial 5 // Journal of Clinical Oncology. – 2002. – Vol. 20, N 24. – P. 4621-4627. https://doi.org/10.1200/jco.2002.09.112

Hackshaw A., Baum M., Fornander T. et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer // J Natl Cancer Inst. – 2009. – Vol. 101, N 5. – P. 341-349. https://doi.org/10.1093/jnci/djn498

Kaufmann M., Jonat W., Blameyc R. et al. On behalf of the Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Survival analyses from the ZEBRA study: goserelin (ZoladexTM) versus CMF in premenopausal women with node-positive breast cancer // European Journal of Cancer. – 2003. – Vol. 39, N 12. – P. 1711-1717. https://doi.org/10.1016/s0959-8049(03)00392-7

Klijn J.G., Blamey R.W., Boccardo F. et al. Combined tamoxifen and luteinising hormone releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials // Journal of Clinical Oncology. – 2001. – Vol. 19, N 2. – P. 343-353.

Leung S.F., Tsao S.Y., Teo P.M. et al. Ovarian ablation failures by radiation: a comparison of two dose schedules // British Journal of Radiology. – 1991. – Vol. 64, N762. – P. 537-538. https://doi.org/10.1259/0007-1285-64-762-537

Pagani O., O'Neil A., Castiglione M. et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI // European Journal of Cancer. – 1998. – Vol. 34, N 5. – P. 632-640. https://doi.org/10.1016/s0959-8049(97)10036-3

Prowell T.M., Davidson N.E. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? // The Oncologist. – 2004. – Vol. 9, N 5. – P. 507-517. https://doi.org/10.1634/theoncologist.9-5-507

Robert N.J., Wang D., Cella S. et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer [abstract] // Proc. Am. Soc. Clin. Oncol. – 2003. – Vol. 22, N 5, A16. – P. 237.

Robert N.J., Wang M., Cella D. et al. Phase III comparison of tamoxifen vs tamoxifen with ovarian ablation in premenopausal women with axillary node negative, hormone receptor positive, breast cancer <=3 cm (INT 0142) [Internet] [abstract 16]. 39th ASCO Annual Meeting; 2003 May 31- Jun 3; Chicago (ILL). 2005 [cited 2007 May 23]: [31 slides]. Available from: http://www.asco.org/portal/site/ASCO.

Roche H., Kerbrat P., Bonneterre J. et al. Complete hormonal blockade versus chemotherapy in pre-menopausal earlystage breast cancer patients (pts) with positive hormonereceptor (HR+) and 1-3 node-positive (N+) tumor: results of the FASG 06 trial // Proceedings of the American Society of Clinical Oncology. – 2000. – Vol. 72a (abstract 279).

Roche H., Kerbrat P., Bonneterre J. et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomized trial // Annals of Oncology. – 2006. – Vol. 17, N 8. – P. 1221-1227. https://doi.org/10.1093/annonc/mdl107

Scottish Cancer Trials Breast Group (1993). Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. // Lancet. – Vol. 341, N 8856. – P. 1293-1298. https://doi.org/10.1016/0140-6736(93)90812-u

Schmid P., Untch M., Kosse V. et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: The TABLE Study // Journal of Clinical Oncology. – 2007. – Vol. 25, N18. – P. 2509-2515. https://doi.org/10.1200/jco.2006.08.8534

Taylor C.W., Green S., Dalton W.S. et al. Multi centre randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptorpositive metastatic breast cancer: An intergroup study // Journal of Clinical Oncology. – 1998. – Vol. 16, N 3. – P. 994-999.

Thomson C.S., Twelves C.J., Mallon E.A. et al. Adjuvant ovarian ablation vs. CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status // The Breast. – 2002. – Vol. 11, N 1. – P. 419-429.

von Minckwitz G., Graf E., Geberth M. et al. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomized trial (GABG trial IV-A-93) // European Journal of Cancer. – 2006. – Vol. 42, N 12. – P. 1780-1788. https://doi.org/10.1016/j.ejca.2006.04.006

Walshe J.M., Denduluri N., Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer // Journal of Clinical Oncology. – 2006. – Vol. 24, N36. – P. 5769-5779. https://doi.org/10.1200/jco.2006.07.2793